Safe Harbour Statement

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the "Group") or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice. Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated. All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto. The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

This document contains statements related to our future business and financial performance and future events and developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations, plans and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those possibly described in the respective disclosures. Should one or more of these or other risks, uncertainties or factors (e.g. events of force majeure, including but not limited to unrest, acts of war, pandemics or acts of God) materialize, plans change or should underlying expectations not occur or assumptions prove incorrect, Siemens Healthineers’ management actions, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the forward-looking statement. This document includes supplemental financial measures that are or may be alternative performance measures not precisely defined in the applicable financial reporting framework (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, and therefore they may not be comparable to those included in this document. Please find further explanations regarding our (supplemental) financial measures in chapter “A.2 Financial performance system” and in the Notes to consolidated financial statements, Note 30 “Segment information” of the Annual Report 2022 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet link https://www.siemens-healthineers.com/investor-relations/presentations-financial-publications.

Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements. This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version.

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice. In the event that the male form is used in this document, the information nevertheless refers to all persons (male, female, non-binary).
Continued impressive order intake – Outlook 2023 confirmed

- **Double-digit equipment order growth in all segments**, equipment book-to-bill at 1.36
- **Soft revenue growth ex-antigen of 1%**, incl. antigen -5%
- **Imaging** with solid growth (5%) and strong margin expansion of +100 bps y-o-y (to 21%)
- **Diagnostics** revenue down by 24% primarily due to declining antigen revenue and China headwinds, margin slightly negative (-2%) due to transformation costs
- **Varian** revenue (-4%) and margin (14%) held back by spillover from Q4 supplier issue
- **Advanced Therapies** with continuous solid growth (5%) and margin (12%)
- **Adj. basic EPS of €0.47**, down y-o-y due to declining antigen contribution
- **Outlook 2023 confirmed**

*Note: All growth rates are year-over-year on a comparable basis, margin refers to adj. EBIT margin, see glossary; equipment orders refer to Imaging, Varian, and Advanced Therapies*
Our unique capabilities

Patient Twinning
Personalization of diagnosis, therapy selection and monitoring, after care and managing health

Precision Therapy
Intelligent and image guided treatment for the most threatening diseases

Digital, Data and AI
Leveraging digital, data and AI and advance providers’ operations with tech-enabled and enterprise services
Our unique capabilities enable breakthrough innovations

### Patient Twinning

- **MAGNETOM Cima.X**
  - Deeper insights with our strongest 3T MRI ever

- **NAEOTOM Alpha**
  - Introducing a new era of Computed Tomography
  - 4 mm Stent
  - Current Technology
  - Photon Counting CT

- **Atellica CI1900**
  - Bringing Atellica technology into low-to-mid volume labs and hub and spoke settings

### Precision Therapy

- **HyperSight**
  - A revolution in resolution and speed in radiotherapy

- **Ethos**
  - Taking the lead in adaptive cancer therapy

- **ARTIS icono**
  - State-of-the-art technology for minimally invasive procedures

### Digital, Data and AI

- **AI-Rad Companion**
  - AI enhanced, automated reading support for radiology

- **Oncology as a service**
  - Comprehensive cloud-based treatment planning services

---

Q1 FY2023
Unrestricted © Siemens Healthineers AG, 2023
Value Partnership with Atrium Health – Capitalizing on the relevance of our unique portfolio and C-level commitment

• Multi-year strategic agreement with Atrium Health to improve access to care, health equity and economic mobility

• Atrium Health to purchase >$200 million in equipment and associated services, including solutions from Imaging, Varian and Advanced Therapies

• Supporting Atrium Health in modernizing its healthcare infrastructure to improve quality of patient care

• Jointly developing education and workforce solutions to help encourage and enhance careers in healthcare

• Jointly improving outcomes, efficiency, quality and reducing costs in healthcare across the enterprise; supported by AI enhanced solutions
Atellica CI1900 completes ecosystem for IA/CC testing – Significant multi-year agreement with Unilabs

- **Atellica Solution** maximizes productivity for high throughput IA/CC testing
- **Atellica CI1900** enables cost-effective integrated testing for low- and mid-volume labs as well as emerging markets
- **Atellica ecosystem** with true standardization enables optimized hub-and-spoke settings
- Atellica platform completion drives portfolio simplification and internal efficiency

- **Multi-year agreement** with Unilabs for IA/CC testing and other testing solutions
- Several hundred analyzers for Unilabs laboratories in Europe; **deal valued at over €200m**
- Agreement includes Atellica Solution and Atellica CI1900, sample handlers and automation solutions

1 Not available for sale in the U.S., product availability may vary from country to country and is subject to varying regulatory requirements
2 IA = Immunoassay, CC = Clinical Chemistry
A unique investment case: Structural and innovation-driven growth paired with attractive earnings growth and resilience

<table>
<thead>
<tr>
<th>Unique resilience</th>
<th>Structural and innovation driven growth</th>
<th>Attractive earnings growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Majority of revenues recurring</td>
<td>Enabling and advancing next level medicine</td>
<td>Sector leading margins in Imaging and Varian with room for expansion</td>
</tr>
<tr>
<td>Strong backlog with increasing contribution of long-term orders from Value Partnerships</td>
<td>Improving productivity for our customers</td>
<td>Margin recovery potential at Diagnostics and Advanced Therapies in the mid-term</td>
</tr>
<tr>
<td>Deeply rooted in all global healthcare systems – balancing short-term variations</td>
<td>Expanding our addressable market</td>
<td></td>
</tr>
</tbody>
</table>

**Structural and innovation driven growth**

- Essential technologies and **leading innovations** for fighting the most threatening diseases
- Continuous tailwind from innovations in pharma and devices which require **better imaging, diagnostics, guidance and monitoring**

**Enabling and advancing next level medicine**

- Essential technologies and **leading innovations** for fighting the most threatening diseases
- Continuous tailwind from innovations in pharma and devices which require **better imaging, diagnostics, guidance and monitoring**

**Improving productivity for our customers**

- Broad portfolio of **innovative technologies** to overcome staff shortage and cost challenges
- Enabling **efficient operations with** digital, data and AI

**Expanding our addressable market**

- Expanding our addressable market by seizing organic and M&A opportunities
- Addressing underserved geographies with **better access and affordability of care**
Soft growth ex-antigen
EPS down due to declining antigen contribution

- Soft revenue growth ex-antigen due to lower Diagnostics volumes mainly in China, and revenue at Varian held back by supplier issue; incl. antigen -5% due to antigen sales declining to €63m (PYQ: €329m)
- Americas at solid 3% growth vs. tough comps (PYQ: 8%)
- EMEA at -16% growth due to declining antigen business (ex-antigen flattish)
- Asia Pacific Japan at 13% growth driven by antigen sales in Japan (ex-antigen solid growth at 4%)
- China at -6% growth impacted mainly by lockdowns and high infection rates

Note: All growth rates are year-over-year on a comparable basis, see glossary
Imaging with solid growth and strong margin expansion; DX with lower antigen contribution and headwinds in China

- Solid growth, in particular very strong growth at Magnetic Resonance
- Margin up y-o-y with strong margin expansion from conversion
- FX tailwind (~100 bps) more than offset by y-o-y increased procurement and logistics costs

**Imaging (€m)**

<table>
<thead>
<tr>
<th>Adjusted revenue</th>
<th>Adj. EBIT (margin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparator Growth</td>
<td>Margin Y-o-Y</td>
</tr>
<tr>
<td>Q1 FY2022: 2,500</td>
<td>Q1 FY2022: 496 (19.8%)</td>
</tr>
<tr>
<td>Q1 FY2023: 2,739</td>
<td>Q1 FY2023: 572 (20.9%)</td>
</tr>
</tbody>
</table>

**Diagnostics (€m)**

<table>
<thead>
<tr>
<th>Adjusted revenue</th>
<th>Adj. EBIT (margin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparator Growth</td>
<td>Margin Y-o-Y</td>
</tr>
<tr>
<td>Q1 FY2022: 1,446</td>
<td>Q1 FY2022: 244 (16.9%)</td>
</tr>
<tr>
<td>Q1 FY2023: 1,147</td>
<td>Q1 FY2023: -25 (-2.2%)</td>
</tr>
</tbody>
</table>

- Revenue down primarily due to antigen sales declining to €63m (PYQ: €329m)
- Revenue excl. antigen declining (-7.3%), mainly impacted by lower testing volumes in China due to lockdowns (beginning of Q1) and high infection rates (end of Q1)
- Margin y-o-y negatively impacted by lower contribution from antigen business, transformation costs (€34m), headwinds in China, FX headwind (~150 bps), and y-o-y increased procurement and logistics costs

**Note:** All growth rates are year-over-year on a comparable basis, see glossary
Varian’s revenue and profit held back as expected; Advanced Therapies with continuous solid growth and margin

Varian (€m)

<table>
<thead>
<tr>
<th></th>
<th>Adjusted revenue</th>
<th>Adj. EBIT (margin)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comparable Growth</strong></td>
<td>-4.5%</td>
<td>-350 bps</td>
</tr>
<tr>
<td><strong>Margin Y-o-Y</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Q1 FY2022</strong></td>
<td>763</td>
<td>137 (18.0%)</td>
</tr>
<tr>
<td><strong>Q1 FY2023</strong></td>
<td>770</td>
<td>112 (14.5%)</td>
</tr>
</tbody>
</table>

- Varian revenue (-4%) held back by spillover from Q4 supplier issue
- Supplier issue resolved in Q1, production back to full capacity
- Margin negatively impacted by held back revenue, FX headwind (~200 bps), and y-o-y increased procurement and logistics costs

Advanced Therapies (€m)

<table>
<thead>
<tr>
<th></th>
<th>Adjusted revenue</th>
<th>Adj. EBIT (margin)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comparable Growth</strong></td>
<td>+5.0%</td>
<td></td>
</tr>
<tr>
<td><strong>Margin Y-o-Y</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Q1 FY2022</strong></td>
<td>437</td>
<td>62 (14.3%)</td>
</tr>
<tr>
<td><strong>Q1 FY2023</strong></td>
<td>474</td>
<td>55 (11.6%)</td>
</tr>
</tbody>
</table>

- Continuous solid growth in Q1 with 5% (FY22 Q4: 6%, Q3 6%)
- Margin negatively impacted by y-o-y increased procurement and logistics costs; FX tailwind (~250 bps)
- Ongoing invest in endovascular robotics

**Note:** All growth rates are year-over-year on a comparable basis, see glossary
Successful focus on pricing will lead to stronger margins in H2
Revenue growth to accelerate from Q2 onwards

Margin improvements skewed towards H2

Growth ex-antigen improving from Q2 onwards

Backlog conversion
- Scheduled backlog for FY23 substantiates expected equipment revenue growth at Imaging, Varian and Advanced Therapies
- Varian additionally with pent-up deliveries after resolution of supplier issue
- China revenue growth to pick up after weak Q1 revenue growth and excellent Q1 order intake

Note: Schematic graphs only, not to scale
Outlook FY2023 confirmed

<table>
<thead>
<tr>
<th>Comparable revenue growth&lt;sup&gt;1, 2&lt;/sup&gt;</th>
<th>Adj. basic earnings per share&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Growth ex antigen&lt;sup&gt;3&lt;/sup&gt;:</strong></td>
<td><strong>Growth ex antigen&lt;sup&gt;3&lt;/sup&gt;:</strong></td>
</tr>
<tr>
<td>6 to 8%</td>
<td>13 to 24%</td>
</tr>
<tr>
<td>~2%</td>
<td>~55ct</td>
</tr>
<tr>
<td>FY2022</td>
<td>FY2022</td>
</tr>
<tr>
<td>5.9%</td>
<td>€2.29</td>
</tr>
<tr>
<td>FY2023E</td>
<td>FY2023E</td>
</tr>
<tr>
<td>-1 to +1%&lt;sup&gt;4&lt;/sup&gt;</td>
<td>€2.00 to €2.20&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

- **Imaging** growth at 7 to 9%
- **Diagnostics**<sup>1</sup> declining -21 to -19% incl. antigen; core growth at 3 to 5%
- **Varian** growth at 9 to 12%
- **Advanced Therapies** growth at 6 to 9%
- **Imaging** margin at 21 to 22.5%
- **Diagnostics**<sup>4</sup> margin at 0 to 3% all-in; core margin at 2 to 4%
- **Varian** margin at 16 to 18%
- **Advanced Therapies** margin at 13 to 15%
- **Financial income, net** at €-150 to €-170m
- **Tax rate** at 26% to 28%

<sup>1</sup> Year-over-year on a comparable basis, excluding currency translation and portfolio effects as well as effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations
<sup>2</sup> The outlook is based on current foreign exchange rate assumptions, on the current portfolio, and on further assumptions, see Quarterly Statement Q1 FY2023
<sup>3</sup> Y-o-y growth excluding antigen contribution
<sup>4</sup> FY2023 assumes €100m revenue of antigen contribution, and €100 to €150m of Diagnostics transformation related one-time costs within adj. EBIT/EPS (total of €150 to €200m costs); core excludes antigen contribution and transformation related one-time costs
Free cash flow negative due to build-up of inventory for equipment revenue in the following quarters

Q1 FY23 Siemens Healthineers EBIT to Free Cash Flow (€m)

CCR\(^1\) 0.04

CRC\(^2\)

Imaging
Diagnostics
< 0
< 0
Varian
< 0
Adv. Therapies
0.6

Healthineers EBIT
PPA amortization
EBIT excl. PPA & amort. intang. excl. PPA
EBITDA
Change in OWC
Change in other assets & liabilities
Add. to operating leases
Other
Operating cash flow pre tax
Add. to intangible assets, PPE
Repayment of 3rd party lease liabilities
FCF pre tax - Repayment of lease liabilities
Repayment of 3rd party lease liabilities
Income taxes
Free cash flow

1 CCR for Healthineers = (Free Cash Flow pre tax - Repayment of 3rd party lease liabilities) / (Healthineers EBIT excl. PPA)
2 CCR for Segments = Free Cash Flow / EBIT

Q1 FY2023
Unrestricted © Siemens Healthineers AG, 2023 | 15
### FY23 balance sheet and net debt bridge

#### Net debt overview

<table>
<thead>
<tr>
<th>in €bn</th>
<th>Sep 30, 2022</th>
<th>Dec 31, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>1.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Receivables from the Siemens Group from financing activities</td>
<td>0.7</td>
<td>1.1</td>
</tr>
<tr>
<td>Short-term and long-term financial debt</td>
<td>(0.7)</td>
<td>(0.7)</td>
</tr>
<tr>
<td>Liabilities to the Siemens Group from financing activities</td>
<td>(13.5)</td>
<td>(13.9)</td>
</tr>
<tr>
<td><strong>Net debt</strong></td>
<td>(12.0)</td>
<td>(12.1)</td>
</tr>
<tr>
<td>Provisions for pensions and similar obligations</td>
<td>(0.7)</td>
<td>(0.6)</td>
</tr>
<tr>
<td><strong>Net debt (incl. pensions)</strong></td>
<td>(12.7)</td>
<td>(12.7)</td>
</tr>
</tbody>
</table>

#### Capital structure development in FY23 (in €bn)

<table>
<thead>
<tr>
<th></th>
<th>1-Oct-22</th>
<th>CF from operating act.</th>
<th>31-Dec-22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pensions</td>
<td>0.7</td>
<td>-0.1</td>
<td>12.7</td>
</tr>
<tr>
<td>Net Debt</td>
<td>12.0</td>
<td>0.2</td>
<td>12.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-0.02</td>
<td></td>
</tr>
</tbody>
</table>

**Leverage**

<table>
<thead>
<tr>
<th></th>
<th>3.0x</th>
<th>3.1x</th>
</tr>
</thead>
</table>

1 Leverage is net debt incl. pension over EBITDA rolling four quarters  | 2 Includes fair values from derivatives
Loan maturity profile

Loans with Siemens Group as of Dec 31\textsuperscript{st}, 2022\textsuperscript{1} (in €m)

![Bar chart showing loan maturity profile with categories: Other, EUR, USD, and detailed amounts for each category across fiscal years]

**Comments**

- Total loan volume ~€13bn equivalent
- Average interest rate ~0.9% p.a.\textsuperscript{3}

**Top 10 loans ranked in € volume**

<table>
<thead>
<tr>
<th>Notional Currency</th>
<th>Volume in m</th>
<th>Volume in €m</th>
<th>Interest rate</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>USD</td>
<td>$1,689</td>
<td>€1,514\textsuperscript{2}</td>
<td>0.26%\textsuperscript{2}</td>
<td>FY 2027</td>
</tr>
<tr>
<td>USD</td>
<td>$1,742</td>
<td>€1,456\textsuperscript{2}</td>
<td>0.08%\textsuperscript{2}</td>
<td>FY 2026</td>
</tr>
<tr>
<td>USD</td>
<td>$1,740</td>
<td>€1,454\textsuperscript{2}</td>
<td>0.59%\textsuperscript{2}</td>
<td>FY 2031</td>
</tr>
<tr>
<td>USD</td>
<td>$1,497</td>
<td>€1,251\textsuperscript{2}</td>
<td>-0.14%\textsuperscript{2}</td>
<td>FY 2024</td>
</tr>
<tr>
<td>USD</td>
<td>$1,486</td>
<td>€1,242\textsuperscript{2}</td>
<td>1.40%\textsuperscript{2}</td>
<td>FY 2041</td>
</tr>
<tr>
<td>USD</td>
<td>$1,247</td>
<td>€1,043\textsuperscript{2}</td>
<td>-0.26%\textsuperscript{2}</td>
<td>FY 2023</td>
</tr>
<tr>
<td>USD</td>
<td>$1,243</td>
<td>€1,039\textsuperscript{2}</td>
<td>0.31%\textsuperscript{2}</td>
<td>FY 2028</td>
</tr>
<tr>
<td>USD</td>
<td>$990</td>
<td>€928</td>
<td>3.44%</td>
<td>FY 2046</td>
</tr>
<tr>
<td>EUR</td>
<td>€850</td>
<td>€850</td>
<td>3.58%</td>
<td>FY 2029</td>
</tr>
<tr>
<td>USD</td>
<td>$998</td>
<td>€834\textsuperscript{2}</td>
<td>2.22%\textsuperscript{2,4}</td>
<td>FY 2024</td>
</tr>
</tbody>
</table>

\textsuperscript{1} Unhedged loans translated to EUR according to spot rate as of Dec 31\textsuperscript{st}, 2022.  
\textsuperscript{2} USD loans addressed by SHS debt & capital restructuring resulting in synthetic EUR debt; EUR volume and interest rates are calculated with underlying hedge rates.  
\textsuperscript{3} Current interest rate across all maturities as of Dec 31\textsuperscript{st}, 2022 is ~0.9% p.a.  
\textsuperscript{4} Floating interest rate – in FY2024, only the hedged €834m loan (out of €2,086m) is based on a floating interest rate
# Provisions for pensions

## Q1 FY2023 Key financials – Pensions and similar obligations

<table>
<thead>
<tr>
<th>in €bn&lt;sup&gt;1&lt;/sup&gt;</th>
<th>FY2018</th>
<th>FY2019</th>
<th>FY2020</th>
<th>FY2021</th>
<th>FY2022</th>
<th>Q1 FY2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defined benefit obligation (DBO)</td>
<td>(3.4)</td>
<td>(3.8)</td>
<td>(3.8)</td>
<td>(4.1)</td>
<td>(3.3)</td>
<td>(3.2)</td>
</tr>
<tr>
<td>Fair value of plan assets</td>
<td>2.6</td>
<td>2.8</td>
<td>2.8</td>
<td>3.3</td>
<td>2.8</td>
<td>2.7</td>
</tr>
<tr>
<td>Provisions for pensions and similar obligations&lt;sup&gt;2&lt;/sup&gt;</td>
<td>(0.8)</td>
<td>(1.0)</td>
<td>(1.0)</td>
<td>(0.9)</td>
<td>(0.7)</td>
<td>(0.6)</td>
</tr>
<tr>
<td>Discount rate</td>
<td>2.9%</td>
<td>1.8%</td>
<td>1.5%</td>
<td>1.7%</td>
<td>4.3%</td>
<td>4.2%</td>
</tr>
<tr>
<td>Interest Income</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Actual return on plan assets (after expenses)</td>
<td>0.1</td>
<td>0.3</td>
<td>0.1</td>
<td>0.2</td>
<td>(0.6)</td>
<td>0.0</td>
</tr>
</tbody>
</table>

<sup>1</sup> All figures are reported on a continuing basis.  
<sup>2</sup> Provisions for pensions and similar obligations does not include net defined benefit assets (Q1 FY2023: €+0.1bn) presented in the line item other assets; Defined Benefit Obligation (DBO) including other post-employment benefit plans (OPEB) of ~€-0.0bn

Q1 FY2023
Unrestricted © Siemens Healthineers AG, 2023 | 18
Adjusted revenue
is defined as consolidated revenue reported in the company’s consolidated statements of income adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.

Comparable revenue growth
is defined as the development of adjusted revenue, respectively, net of currency translation effects, which are beyond our control, and portfolio effects, which involve business activities that are either new to our business or no longer a part of it.

EBITDA
is defined as income before income taxes, interest income and expenses, other financial income, net as well as amortization, depreciation & impairments.

Adjusted EBIT (adj. EBIT)
is defined as income before income taxes, interest income and expenses and other financial income, net, adjusted for expenses for portfolio-related measures, severance charges. In addition, centrally carried pension service and administration expenses are excluded from adjusted EBIT of the segments.

Adjusted EBIT margin (adj. EBIT margin)
is defined as the adjusted EBIT, divided by its adjusted total revenue.

Adjusted basic earnings per share (adj. basic EPS)
is defined as basic earnings per share, adjusted for portfolio-related measures and severance charges, net of tax.

Free cash flow (FCF)
comprises the cash flows from operating activities and additions to intangible assets and property, plant and equipment included in cash flows from investing activities.

Please find further explanations regarding our financial key performance indicators in chapter “A.2 Financial performance system” and in the notes to the consolidated financial statements Note 30 “Segment information” in the Annual Report of 2022 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet link https://www.siemens-healthineers.com/investor-relations/presentations-financial-publications.